For the twelve months ended Jun 30, 2026, Orthofix Medical Inc. reported $833.19M of revenue and -$61.72M of net income.
OFIX revenueQ2 2026$210.93M
- Quarter YoY
- +3.8%
- QoQ
- +7.2%
- FY YoY
- +2.9%
- 5Y CAGR
- +15.1%
- 10Y CAGR
- +7.6%
OFIX revenue was $210.93M in fiscal Q2 2026 (ended Jun 30, 2026), up 3.8% from a year earlier and up 7.2% from the prior quarter. For the full fiscal 2025 it was $822.31M, up 2.9% from fiscal 2024. Compound annual growth was +15.1% over 5 years and +7.6% over 10 years. It rose in 8 of the last 10 fiscal years. Fiscal 2025 is the highest of the 15 fiscal years on file.
OFIX net incomeQ2 2026-$15.80M
OFIX net income was -$15.80M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$14.08M a year earlier. For the full fiscal 2025 it was -$92.19M, compared with -$126.00M in fiscal 2024.
OFIX EPSQ2 2026-$0.39
OFIX diluted EPS was -$0.39 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.36 a year earlier. For the full fiscal 2025 it was -$2.33, compared with -$3.30 in fiscal 2024.
OFIX free cash flowQ2 2026-$18.87M
OFIX free cash flow was -$18.87M in fiscal Q2 2026 (ended Jun 30, 2026), compared with $4.53M a year earlier. For the full fiscal 2025 it was -$1.28M, compared with -$9.09M in fiscal 2024.
Source: XBRL data Orthofix Medical Inc. files with the SEC, latest filing dated Aug 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.